EVER Stock Cash Flow Statements

EverQuote Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

EverQuote Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30

cash flows from operating activities:
net income	14,701,000	7,990,000	12,306,000	11,554,000	6,402,000	1,907,000	-6,348,000	-29,217,000	-13,193,000	-2,529,000	-8,494,000	-6,451,000	-3,756,000	-5,715,000	-8,480,000	-5,272,000	-1,881,000	-3,801,000	-3,768,000	-3,184,000	-2,808,000	-1,442,000	-934,000	173,000	-1,974,000	-4,382,000	-6,925,000	-3,808,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization expense	918,000	1,221,000	1,555,000	1,618,000	1,236,000	1,263,000	1,075,000	2,251,000	1,463,000	1,407,000	1,522,000	1,410,000	1,405,000	1,511,000	1,464,000	1,298,000	1,136,000	1,174,000	1,176,000	731,000	594,000	849,000	593,000	588,000	524,000	481,000
stock-based compensation expense	6,560,000	5,420,000	5,310,000	5,446,000	5,340,000	4,518,000	4,813,000	5,644,000	7,130,000	6,509,000	6,623,000	7,233,000	7,600,000	7,530,000	7,063,000	8,348,000	7,089,000	7,520,000	6,189,000	7,200,000	6,250,000	4,540,000	3,464,000	3,269,000	3,238,000	2,750,000	3,245,000	2,586,000
benefit from bad debt			-3,000	8,000	-10,000	18,000		-38,000	-21,000	245,000									90,000	-2,000	-4,000	21,000	-1,000	57,000
unrealized foreign currency transaction (gains) losses	75,000	35,000	-82,000	59,000	1,000	-4,000					25,000	-18,000						15,000
litigation accrual settled with sale of assets
changes in operating assets and liabilities:
accounts receivable	6,843,000	-457,000	-13,099,000	-219,000	-9,737,000	-17,123,000	952,000	-63,000	17,157,000	-9,827,000	10,239,000	-3,878,000	9,974,000	-10,973,000	8,849,000	1,365,000	3,239,000	-2,942,000	-4,642,000	-5,036,000	-830,000	-3,462,000	-2,305,000	-5,818,000	1,287,000	-8,396,000	4,329,000	-4,070,000
prepaid expenses and other current assets	-1,491,000	496,000	128,000	-1,002,000	342,000	972,000	-1,675,000	770,000	158,000	1,709,000	-815,000	-1,046,000	-114,000	-136,000	-2,701,000	-849,000	-264,000	172,000	-1,425,000	-1,588,000	3,730,000	-94,000	-3,855,000	-1,781,000	-131,000	158,000	189,000	327,000
commissions receivable, current and non-current	859,000	1,014,000	1,158,000	1,078,000	1,321,000	1,323,000	1,565,000	2,740,000	-724,000	595,000
operating lease right-of-use assets	281,000	267,000	371,000	590,000	755,000	497,000	491,000	632,000	686,000	688,000	662,000	664,000	642,000	645,000	674,000	636,000	609,000	791,000
other assets			0	0			385,000	0	0	36,000	14,744,000	-3,511,000	-5,691,000	-5,561,000	-9,805,000	-749,000	393,000	-733,000	-332,000	-165,000	-53,000	-4,000	1,000
accounts payable	1,747,000	-2,765,000	12,961,000	5,220,000	8,615,000	15,868,000	-3,382,000	-2,217,000	-7,816,000	4,000	-6,496,000	4,207,000	-9,883,000	13,296,000	4,654,000	-1,499,000	-6,421,000	-702,000	-729,000	6,737,000	-690,000	3,983,000	305,000	5,003,000	-3,102,000	4,631,000	2,538,000	-799,000
accrued expenses and other current liabilities	-12,306,000	10,018,000	-73,000	75,000	-832,000	1,870,000	1,979,000	-3,791,000	-583,000	852,000	891,000	-1,207,000	798,000	-2,857,000	-7,123,000	2,277,000	4,728,000	2,810,000	-1,643,000	925,000	-2,761,000	-489,000	6,712,000	3,061,000	-687,000	1,040,000	-43,000	504,000
deferred revenue	-454,000	335,000	-14,000	-120,000	29,000	-2,000	-29,000	92,000	-138,000	80,000	-23,000	-84,000	-10,000	-112,000	204,000	56,000	24,000	-57,000	177,000	59,000	56,000	76,000	-66,000	-194,000	91,000	230,000	371,000	-83,000
operating lease liabilities	-277,000	-268,000	-384,000	-693,000	-793,000	-667,000	-658,000	-705,000	-741,000	-902,000	-749,000	-779,000	-692,000	-663,000	-772,000	-731,000	-699,000	-638,000
net cash from operating activities	25,297,000	23,306,000	20,134,000	23,614,000	12,378,000	10,440,000	-792,000	-4,147,000	3,348,000	-1,237,000	-4,898,000	-3,520,000	-3,528,000	-3,845,000	-6,859,000	2,813,000	7,715,000	3,520,000	-3,235,000	5,995,000	3,981,000	3,927,000	3,956,000	4,299,000	-360,000	-3,482,000	4,109,000	-5,007,000
capex	-1,505,000	-925,000	-1,003,000	-1,724,000	-532,000	-745,000	-852,000	-955,000	-1,015,000	-940,000	-1,038,000	-1,235,000	-1,585,000	-372,000	-534,000	-1,032,000	-533,000	-777,000	-1,114,000	-837,000	-986,000	-885,000	-777,000	-646,000	-885,000	-667,000	-1,192,000	-834,000
free cash flows	23,792,000	22,381,000	19,131,000	21,890,000	11,846,000	9,695,000	-1,644,000	-5,102,000	2,333,000	-2,177,000	-5,936,000	-4,755,000	-5,113,000	-4,217,000	-7,393,000	1,781,000	7,182,000	2,743,000	-4,349,000	5,158,000	2,995,000	3,042,000	3,179,000	3,653,000	-1,245,000	-4,149,000	2,917,000	-5,841,000
cash flows from investing activities:
acquisition of property and equipment, including costs capitalized for development of internal-use software	-1,461,000	-1,133,000	-1,003,000	-1,489,000	-852,000	-770,000	-852,000	-966,000	-1,015,000	-1,007,000	-1,071,000	-1,230,000	-1,308,000	-681,000	-587,000	-965,000	-533,000	-777,000	-1,114,000	-837,000	-986,000	-885,000	-777,000	-646,000	-885,000	-667,000	-1,192,000	-1,081,000
net cash from investing activities	-1,461,000	-1,133,000	-1,003,000	-1,489,000	-852,000	-770,000	-852,000	12,228,000	-1,015,000	-1,007,000	-1,071,000	-1,230,000	-1,308,000	-681,000	-587,000	-16,920,000	-533,000	-777,000	-1,114,000	-15,767,000	-986,000	-885,000	-777,000	-646,000	-885,000	-667,000	-1,192,000	-1,081,000
cash flows from financing activities:
proceeds from exercise of stock options	373,000	1,962,000	651,000	288,000	1,186,000	1,428,000	639,000	0	53,000	287,000	212,000	122,000	50,000	558,000	524,000	1,367,000	452,000	1,272,000	1,345,000	1,244,000	954,000	1,364,000	926,000	1,173,000	649,000	234,000	8,000	276,000
tax withholding payments related to net share settlement	-986,000	-1,293,000	-496,000	-507,000	-414,000	-429,000	-103,000	-67,000	-102,000	-130,000	-21,000	-28,000
net cash from financing activities	-613,000	669,000	155,000	-219,000	772,000	999,000	536,000	-67,000	-49,000	157,000	191,000	94,000	-1,000	15,558,000	524,000	1,367,000	452,000	1,272,000	1,345,000	1,244,000	954,000	1,364,000	926,000	1,173,000	649,000	234,000	8,000	42,415,000
effect of exchange rate changes on cash, cash equivalents and restricted cash	-3,000	10,000	-11,000	16,000	1,000	-5,000	15,000	-13,000	11,000	5,000	22,000	-22,000	-22,000	-5,000	0	-7,000	0	1,000
net increase in cash, cash equivalents and restricted cash	23,220,000	22,852,000	19,275,000	21,922,000	12,299,000	10,664,000	-1,093,000	8,001,000	2,295,000	-2,082,000		-4,678,000	-4,859,000	11,027,000			7,634,000	4,016,000	-3,011,000	-8,528,000	3,949,000	4,406,000	4,105,000	4,826,000	-596,000	-3,915,000
cash, cash equivalents and restricted cash at beginning of period	0	102,116,000	0	0	0	37,956,000	0	0	0	30,835,000	0	0	0	35,101,000	0	0	0	43,120,000	0	0	0	46,304,000	0	0	0	41,884,000
cash, cash equivalents and restricted cash at end of period	23,220,000	124,968,000	19,275,000	21,922,000	12,299,000	48,620,000	-1,093,000	8,001,000	2,295,000	28,753,000	-5,756,000	-4,678,000	-4,859,000	46,128,000	-6,922,000	-12,747,000	7,634,000	47,136,000	-3,011,000	-8,528,000	3,949,000	50,710,000	4,105,000	4,826,000	-596,000	37,969,000
supplemental disclosure of non-cash information:
acquisition of property and equipment included in accounts payable and accrued expenses and other current liabilities	-44,000	208,000		-235,000	320,000	25,000		11,000
assets sold in settlement of litigation accrual
operating lease liabilities arising from obtaining right-of-use assets			0	1,332,000							0	0	529,000	567,000	0	143,000	0	240,000
supplemental disclosure of non-cash investing information:
loss on sale of health assets							0
impairment of right-of-use asset							0
change in fair value of contingent consideration liabilities							0	0	-37,000	-113,000		-95,000	-3,780,000	-892,000
proceeds from sale of health assets							0
proceeds from private placement of common stock											0	0	0	15,000,000
supplemental disclosure of cash flow information:
cash paid for income taxes
supplemental disclosure of noncash investing and financing information:
acquisition of property and equipment included in accounts payable										67,000	33,000	-5,000	-277,000	309,000	53,000	-67,000
issuance of class a common stock to settle contingent consideration liabilities
issuance of class a common stock in settlement of stock-based compensation liability
deferred taxes															0
benefit from (recovery of) bad debt											581,000	35,000	2,000	75,000	9,000	0	-4,000	-46,000
changes in operating assets and liabilities, net of effects from acquisition:
other long-term liabilities															-964,000	26,000	-32,000	36,000	51,000	318,000
acquisition of business															0				0
fair value of contingent consideration in connection with acquisition included in liabilities
reconciliation of cash, cash equivalents and restricted cash:
cash and cash equivalents											-5,756,000	-4,678,000	-4,859,000	46,128,000	-6,922,000	-12,747,000	7,634,000	46,886,000	-3,011,000	-8,528,000	3,949,000	50,460,000
restricted cash															0	0	0	250,000	0	0	0	250,000
total cash, cash equivalents and restricted cash shown in the statement of cash flows											-5,756,000	-4,678,000	-4,859,000	46,128,000	-6,922,000	-12,747,000	7,634,000	47,136,000	-3,011,000	-8,528,000	3,949,000	50,710,000
unrealized foreign currency transaction gains
supplemental disclosure of non-cash investing and financing information:
unrealized foreign currency transaction losses										9,000				7,000
change in fair value of contingent consideration															60,000	425,000	-210,000	-79,000
changes in operating assets and liabilities, net of effects from acquisitions:
net decrease in cash, cash equivalents and restricted cash
fair value of contingent consideration in connection with acquisition included in stockholders' equity
issuance of class a common stock to settle stock-based compensation liability
direct channels
indirect channels
fair value of contingent consideration in connection with acquisition included in accrued expenses and other long-term liabilities
loss on disposal of property and equipment
fair value of contingent consideration in connection with acquisition included in stockholders’ equity
fair value of contingent consideration in connection with acquisition included in other long-term liabilities																			0
fair value of contingent consideration in connection with acquisition included in equity
computer equipment
software
furniture and fixtures
leasehold improvements
deferred rent																						-51,000	-56,000	-57,000	-28,000	6,000	18,000	-6,000
noncash interest expense																											0	0
proceeds from initial public offering, net of underwriting discounts and commissions																											0
proceeds from borrowings on line of credit																											0	0
repayments of borrowings on line of credit																											0	-6,983,000
repayments of term loan																											0	0
payments of initial public offering costs																											0	-3,191,000
supplemental disclosure of cash flow information
cash paid for interest
conversion of convertible preferred stock to common stock																											0
accretion of redeemable convertible preferred stock to redemption value																											0	0
purchases of property and equipment included in accounts payable																												247,000
deferred initial public offering costs included in accounts payable or accrued expenses
repurchase of common stock
conversion of series b redeemable convertible preferred stock to series b-1 redeemable convertible preferred stock
retirement of treasury stock
depreciation and amortization																												342,000
net increase in cash and cash equivalents
cash and cash equivalents at beginning of period
cash and cash equivalents at end of period
net increase in cash
cash at beginning of period
cash at end of period
conversion of series a redeemable convertible preferred stock to common stock
accrued advertising expenses
accrued employee compensation and benefits
accrued professional fees
other current liabilities

We provide you with 20 years of cash flow statements for EverQuote stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of EverQuote stock. Explore the full financial landscape of EverQuote stock with our expertly curated income statements.

The information provided in this report about EverQuote stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.